Immusoft's mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP™). The technology modifies a patient's B cells and instructs the cells to produce gene-encoded medicines (biologics). The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/03/19 | $20,000,000 | Series B |
Alexandria Venture Investments Breakout Ventures DEFTA Partners Mesa Verde Venture Partners RBV Capital | undisclosed |
